Clavulanic

Medication eg cream or ointment ; is rarely necessary, and is usually less effective than hygiene measures for treating balanitis. The aim is to make it difficult for organisms to grow under the foreskin by keeping the glans and the foreskin clean and dry. Once a day, ideally when you have a shower, slide your foreskin back towards your body until the glans is completely uncovered Figures 1a and 1b ; . Do not use any force. If there is any resistance or discomfort, check with a doctor. Wash the end of your penis and foreskin thoroughly using warm water only. Alternatively, sorbolene and glycerine cream available from chemists and supermarkets ; may be used as a substitute for soap. After washing, dry the end of the penis and foreskin thoroughly. If convenient, sit with the glans exposed to the air for 10 minutes. More thorough drying can be achieved by using a fan or hair dryer Figure 2 ; . After drying, replace the foreskin Figure 3 ; . When you urinate, slide the foreskin back so that urine does not wet the foreskin Figure 4 ; . After urination, dry the end of the penis and replace the foreskin. If you are prone to developing balanitis a few hours after sex, wash the penis as described above shortly after having sex. Make sure the glans is completely dry before replacing the foreskin.

Somebody's dying, what possible difference could it make if they were a damn drug addict? That's the legacy of NancyFucking-Reagan, a country where we're so psycho about `drug addicts' that we sentence millions to be tortured to death. Doctors are so freaked about the DEA that they won't write the scrips. People are in absolute agony, and what they get is sanctimonious babbling about the `war on drugs.' and irbesartan, because clavulanic acid production. Accordingly, the present invention provides clavulanic acid as hereinbefore described and its salts and esters. News Home Top Stories U.S. National Business World Entertainment Sports Technology Politics Science Health Weight Loss and avodart. She asked if i had checked the side effects of the new medication i started a few days prior.
Design: Prospective ? ; clinical No. of pre-ESRD subjects: 239 trial before after study; may be patients followed diet for at least 3 retrospective ; months and were included in the analysis Intervention s ; studied: Supplemented very low-protein Inclusion criteria: Advanced chronic diet SVLPD ; , as follows: renal failure GFR 25 ml min 1.73 2 Protein: 0.3 g kg day, of m ; vegetable origin; Exclusion criteria: Immediate need Phosphorus: 5-7 mg kg day; Energy: 35 kcal kg day, in mix for hemodialysis; severe co-morbid conditions; "obviously incapable" of of 67% carbohydrates, 30% following diet and monitoring lipids, and 3% protein; Supplemental essential amino schedule acids and ketoanalogs, 1 tablet 5kg day; Age mean SD ; : 50.2 15.6 Supplemental calcium carbonate 400 mg elemental Sex: 59% M, 41% F Supplemental iron + multivitamin. Race: NR and dutasteride. Check patient medication records for indications of coronary artery disease. Recommend that patients talk to their physicians about switching to newer SUs, which claim to be selective for cells in the pancreas and therefore reduce risk to the heart muscle during ischemic events. ? ? Managed the DuPont Pharmaceuticals Company account, which consisted of several consulting projects, with total revenues exceeding $1 million. ? ? Loaded MedDRA, WHODrug, and the COSTART dictionaries into the Thesaurus Management System TMS ; for numerous clients. ? ? Taught the following courses: Introduction to Oracle Clinical 4.0 ; , Oracle Clinical Advanced Procedures, TMS 4.0 Overview, TMS 4.0 Loading Dictionaries ? ? Conducted the Oracle Clinical 10 day Workshop and abacavir. Determined by broth tube dilution procedure using two-fold dilutions of metabolite in Sabouraud dextrose broth9. The antifungal activity was seen both on solid as well as in culture broth unlike fumaramidmycin, which is inactivated in the fermentation broth 21 . Production of antifungal metabolite has been known to be influenced by media components and cultural conditions, such as aeration, agitation, pH, temperature and glycerol concentration, which vary from organism to organism22 . Cultural conditions were found to affect antifungal metabolite production by Streptomyces rochei AK 39. The change in pH of the culture medium induces production of new substances that affect antibiotic production 23. The production of helvoic acid and cerulenin by Cephalosporium caeruleus was affected by change in the pH 24 . Streptomyces rochei AK 39, the optimum temperature for metabolite production and growth was the same i.e., 37 oC. Deviation from optimum temperature for antifungal metabolite production severely affects the yield of the antifungal metabolite 25. Agitation affects aeration and mixing of the nutrients in the fermentation medium. Adequate agitation 200 rpm ; was found to increase antifungal metabolite production in the present study. The yield of cephalosporin C is known to be increased with increased agitation26 . Maximum production of metabolite 400 AU ml ; was achieved in late log phase, which remained constant during stationery phase. Antibiotic production usually occurs in the stationery phase 27. In our case, the production of the metabolite by Streptomyces rochei AK 39 took place during the late log phase of growth in the fermentation medium indicating that the metabolite production was directly proportional to the growth rate. Accumulation of antibiotics, cephalomycin C and clavulanic acid has been shown to occur in parallel with growth in a defined medium 28. The antifungal metabolite was active in solid as well as liquid media and it was extracted by ethyl acetate from the culture supernatant, whereas the ethanol extract of the biomass showed no antifungal activity, thus showing the extracellular nature of the metabolite. Mostly antibiotics are extracellular29. Further studies on the.

Thiazides, ACE inhibitors and beta-blockers all reduce cardiovascular morbidity and mortality in patients with hypertension and diabetes and are suitable first-line agents in people without renal disease.11, 13, 2123 Subgroup analyses of comparative outcomes trials have not demonstrated any cardiovascular morbidity or mortality advantage of ACE inhibitors over thiazides in people with diabetes.11, 22 Beta-blockers are also appropriate first-line agents in people with both diabetes and hypertension21, 22 and are particularly indicated in people with a history of recent myocardial infarction. Bear in mind that beta-blockers may predispose some treated diabetics to hypoglycaemia and mask the adrenergic warning signs of hypoglycaemia tremor and tachycardia and ziagen. Also, consider how much money you spend each day on things that are doing harm to your body. Whether it's the morning Latte from Starbucks, the pack of cigarettes, or the drive-thru trip for McDonald's, Americans spend well above $4 per day on items that are detrimental to our health. Are you going to continue to be a part of this trend, or are you going to make a change for the better?, for example, amoxicillin with clavulanic acid. Toward benzylcant decrease in catalytic efficiency kcat Km ; penicillin and aminopenicillins, whereas the catalytic efficiency toward carboxypenicillin is conserved. In constrast, the hydrolysis of all the cephalosporins tested is unmodified by the mutation. Both the kcat and the affinity constant K , remain similar for the K234R mutant and TEM-1enzyme. Interactions with Ckavulanic Acid-Clavulanic acid is the first inhibitor effective in vitro as well as in vivo when combined withamoxicillin or ticarcillin. The competitive and irreversible inhibition can be fitted to Scheme1 31, 32 and acarbose. If you go off this anxiety drug too quickly you may suffer very uncomfortable withdrawal symptoms! Page 67. Atrovent ipratropium bromide Atrovent HFA ipratropium Augmentin amoxicillin, clavulanic potassium Augmentin XR .amoxicillin, clavulanic potassium Avalide hydrochlorothiazide, irbesartan Avandamet metformin HCl, rosiglitazone maleate Avandaryl glimepiride, rosiglitazone Avandia rosiglitazone maleate Avapro irbesartan Avastin bevacizumab Avelox moxifloxacin HCl Avelox IV .moxifloxacin HCl Aviane ethinyl estradiol, levonorgestrel Avinza morphine Avodart dutasteride Avonex interferon beta 1a Axert almotriptan malate Axid nizatidine * Azactam aztreonam Azelex azelaic acid Azmacort triamcinolone acetonide Azopt . inzolamide Azulfidine sulfasalazine * B B-D Test Strips non-pharmaceutical ingredient Baciim bacitracin Bactroban Nasal mupirocin calcium Balanced Salt Plus . lcium, glucose, glutathione, magnesium, potassium, sodium Baraclude entecavir Bayrab antirabic serum Beconase AQ .beclomethasone dipropionate monohydrate Benefix factor ix Benemid probenecid * Benicar olmesartan medoxomil Benicar HCT hydrochlorothiazide, olmesartan medoxomil and precose.
Wang SK, Tsiatis AA 1987 ; Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 39: 193199. Whitehead J 1999 ; On being the statistician on a data and safety monitoring board. Statistics in Medicine 18: 34253434. Zapol WM, Snider MT, Hill JD et al. 1979 ; Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. Journal of the American Medical Association 242 20 ; : 21932196.

Back Review Group for Spinal Disorders Esmail Inflammatory Bowel Disease Review Group Musculoskeletal Review Group Neonatal Group Health Promotion Field RCT Quality Assessment Methods Working Group Dr. Claire Bombardier Ms. Rosmin Dr. Jack McDonald Ms. Lorinda Simms Dr. Peter Tugwell Ms. Bev Shea Dr. Jack Sinclair Ms. Diane Haughton Dr. Alba DiCenso Ms. Sheila McNair Dr. David Moher and acenocoumarol and clavulanic, because clavulanic acid 875 mg.
Older adult R group with which to compare, the Gb levels of older C monkeys appeared to increase over the same time period as well. It is possible that small but significant DR-induced reductions of Gb in younger adulthood may be attenuated with increasing age in nonhuman primates. It is not clear whether age or differences in feeding protocol explain the findings of Bodkin et al. 6 ; , who reported no reduction in Gb after 9 yr of weight clamping i.e., maintaining body weight at a constant level by titrating energy intake ; . Ib levels were markedly reduced for R monkeys; in contrast, Ib of the normoinsulinemic C group increased and then appeared to level off for a few years, consistent with findings reported by Lane et al. 29 ; . The decline in Ib in both C and R groups at the 5.5-yr assessment is likely due to the change to a more specific insulin RIA at that time; however, among C monkeys, the mean Ib level subsequently rose to pre-5-yr levels, whereas in the R monkeys, Ib remained at lower levels. When the lower Ib levels are taken into account after the change in insulin assay in both groups, these data suggest an increase in Ib with age among ad libitum-fed normoinsulinemic monkeys with perhaps little, if any, rise observed among the R animals. As observed in other chronically restricted monkeys 29 ; , the acute plasma insulin response to glucose was also elevated among C vs. R monkeys. This difference was evident both before and after the change in insulin assay. The apparent drop in insulin response values among R monkeys after this change may be responsible, in part, for the elevated SI levels from 5.5 yr on. However, the apparent reduction in insulin response values among controls at 5.5 yr did not result in a sustained enhancement of SI. Furthermore, because the substantial increase in SI among R monkeys is evident 6 mo earlier i.e., at 5 yr ; , it more likely that this was due to the small reduction in food allotment following the 4.5-yr assessment period. Likewise, an increase in SI was seen after the reduction in food allotment in R monkeys after 1.5 yr. It is reasonable to speculate that SI levels may also reflect an adaptation to chronic DR. In agreement with our findings that SI was markedly increased and insulin responses were reduced in R monkeys within 1 yr of reestablishing 30% difference in energy intake between treatment groups, Cefalu et al. 8 ; also reported SI to be significantly improved after only 1 yr of adult cynomolgus monkeys. Likewise, Bodkin et al. 6 ; reported enhanced maximally insulin-stimulated glucose uptake as measured during a hyperinsulinemic euglycemic clamp procedure. Although this measure is not directly comparable with the minimal-model-derived SI, they are highly correlated 4, 15 ; . Agreement of these findings from studies with such diverse methodologies and among animals of varied ages and species further suggests a protective effect of energy restriction on the development of insulin resistance with increasing age. Moreover, the elevated fasting insulin and insulin response levels among ad libitum-fed C monkeys suggests a potentially greater exposure of these animals to insulin.
Objectives: ESBL producing Enterobacteriaceae have compromised therapy with b-lactam antibiotics, including third generation of cephalosporins. The objective of this study was to determine the occurence of ESBL phenotypes among different isolates of Enterobacteriaceae and their susceptibility to antimicrobial agents. Materials and Methods: A total of 1000 strain of Enterobacteriaceae were isolated from urine samples during 1-year period. Suspected strains are presumptively defined as ESBL producers according to result of disk diffusion method, using ESBL marker antibioticsceftazidim, ceftriakson and cefotaksim. Those isolates were retested with double-disc sinergy test DDST ; -CAZ, CTR, CTX and amoxicillin-clavulanic acid disks implementation. Enhancement of inhibition zone or so-called ghost zone ; indicated presence of ESBL strain. Antimicrobials susceptibility to b-lactam antibiotics, aminoglikosides, quinolones and trimetoprim-sulfametoxazol evaluated by disc-diffusion method, and the ESBL detection was performed by the DDST, according to NCCLS criteria 2002 ; . Results: The species distribution as follows: Escherichia coli 63.9% ; , Klebsiella spp. 30% ; , Enterobacter spp. 11.1% ; , Proteus vulgaris 2.3% ; , P. mirabilis 11% ; , Providencia spp. 0.8% ; , Morganella morgani 0.2% ; and Citrobacter spp. 2.6% ; . Total number of isolates 21.4% ; was multiresistant for more than three groups of antibiotics: E. coli were 44.39%, Klebsiella spp. 8.41%, Enterobacter spp. 26.63%, P. vulgaris 5.14%, P. mirabilis 10.28%, Providencia spp. 2.33%, M. morgani 0.46% and Citrobacter spp. 35%. Thirtythree per cent of all isolates were from hospital samples; 4.3% of all isolates were producing ESBL, and included four different species. Escherichia coli 4.06% ; , Klebsiella 23.3% ; , Enterobacter 8.1% ; and Proteus mirabilis 0.2% ; . The majority of producers were from clinical specimens 63% ; . Conclusions: Gram-negative rods were responsible for high percentage of urinary tract infections. Escherichia coli was the most common uropathogen. Multiresistant strain represent 21.4% from Enterobacteriaceae implicated in UTI. The resistance to ampicilin was the most frequent and concerned 62.6% of isolates of all indicated species and acetylsalicylic.

Several groups active during the early clinical assessment of EMB commented upon the difficulties encountered in assessing the development of ocular toxicity due to EMB Ferebee, Doster & Murray, 1966; Bobrowitz & Robins, 1967; Doster et al., 1973 ; . Even among patients who were not receiving EMB, changes in visual acuity were quite commonly documented, and in several clinical trials where the clinicians were blinded to the allocation of patients, ocular "toxicity" was recorded among the control groups. The possibility of toxicity would be sufficient to prompt careful clinicians to stop the drug; Ferebee, Doster & Murray 1966 ; referred to this as a "psychological" hazard. Early studies of the use of EMB tended to be fairly precise in describing how toxicity was assessed; by contrast, some later studies either make no specific mention of ocular toxicity and its assessment, or carried out formal assessment only if patients presented with complaints of visual disturbances. Nevertheless, there is no doubt that the ocular toxicity of EMB is dose-related and that, although incidence declines as the dose declines, ocular toxicity has been encountered at all EMB doses in clinical use. There are case reports of confirmed cases of ocular toxicity occurring at an EMB dose of 15 mg kg: the data but not the case reports ; are summarized in Table 2. We invite you to join us in the morning of March 24, 2007 for a Patients' Forum. Speakers include Dr. Alice Cheng, endocrinologist and member of Thry'vors medical advisory panel; Loraine Warnock, registered nurse, and senior team member of nuclear medicine department at London Health Sciences Centre; and our own Rhonda McMahon - thyca survivor residing and working in Guelph, Ontario. As well, if you are currently a volunteer with Thry'vors or have an interest in finding out more about becoming one, we encourage you to stay for afternoon sessions with us -- Volunteers' Day. We are planning for relaxation activities, a volunteer appreciation ceremony, and opportunities to get to know fellow survivors in a smaller group. Registration for both the Patients' Forum and Volunteers' Day sessions are separate, but both mandatory for participation. 1. To register for the Patients' Forum, complete the form that came with this newsletter. 2. To register for the Volunteers' Day activities, complete the special form enclosed, or contact Jasna Schwind at 416-289-5000 ext. 8082. The Patients' Forum and Volunteers' Day activities are supported by an unrestricted grant from Genzyme Canada Inc. Was made possible by combining recombinant factor VIII Kogenate FS ; with PEGylated liposomes to create a new longer acting product called BAY 79-4980. This new product was developed through an agreement between Bayer Pharmaceutical and Zilip-Pharma. ZilipPharma developed and refined PEGylated liposome technology. Liposomes were discovered about 30 years ago. They are sub-microscopic size spherical vesicles hollow balls ; , with a fat-like phospholipid ; membrane and an aqueous water-like ; core. Certain drugs can be incorporated into the liposomes, which then act like tiny shuttles in the blood, transporting these drugs to the area of need within the body. The new factor VIII BAY 79-4980 uses a second technology called PEGylation. Described in 1977, molecules of ethylene glycol are strung together like beads on a string to make large molecules polymers ; called polyethylene glycol PEG ; . Certain drugs can be attached to these polymers, which can escape the body's immune system and prolong the drug's circulation time in the blood. Zilip Pharma has created PEGylated liposomes by coating liposomes with PEG. These PEGylated liposomes are not as readily eliminated from the body. Therefore drugs attached to these PEGylated liposomes are likely to circulate in the blood for a longer period of time. BAY 79-4980 uses recombinant factor VIII Kogenate FS ; attached to the pegylated liposomes.

I an entrepreneurial pharmaceutical and biotechnology professional, with 13 years successfully leading applied research; clinical trials; product development; intellectual property; corporate strategy; and business development programs. My multi-disciplinary training and professional experience is ideally suited to the design and execution of corporate strategy, organizational structure and pharmaceutical development programs for start-ups, small pharma and new business units within large companies Eastman Chemical Co. Business Builder Award, 2004 ; . Some of my key attributes include: Exceptional analytical, organizational, writing, communication and presentation skills. Extensive interactions worldwide with banks, investors, M&A candidates, corporate partners major pharma, licensees, medical practitioners, patients, scientists, CROs, attorneys, service providers and other collaborators. Detailed drug discovery, drug delivery, preclinical and clinical development experience, with over 20 clinical studies in diverse therapeutic areas. Registered US Patent Agent.

At the online med pharmacy, your health is our speciality, for instance, cefixime clavulanic.

Notice: healthsquare is solely to be used as an informational resource and should never be used to replace contact with your licensed healthcare provider. ASER SUBEPITHELIAL KER atomileusis LASEK ; is a newly advocated laser refractive procedure for patients with myopia in whom photorefractive keratectomy PRK ; or laser in situ keratomileusis may not be ideal because of their drawbacks.1, 2 These drawbacks may include subepithelial haze, postoperative discomfort, and prolonged visual recovery for patients who undergo PRK and who have flap complications and or diffuse lamellar keratitis, and epithelial ingrowth for patients who undergo laser in situ keratomileusis.3-6 Laser in situ keratomileusis and PRK also may be unsuitable refractive choices for certain patients who have corneal thinning or for patients.

The concentrations of clavuoanic acid and amoxicillin were determined in sera and different abdominal tissues of 17 patients who underwent elective colorectal surgery. Patients were randomly allocated to two groups. At the time of induction of anesthesia, patients in group 1 were given 200 mg of clavulanic acid with 2, 000 mg of amoxicillin and patients in group 2 received 400 mg of clavulanic acid with 2, 000 mg of amoxicillin. In both groups, the initial dose was administered again after 2 h. Blood samples were collected to determine peak and trough antibiotic levels. Serial blood samples were also collected at predetermined periods opening and closure of the abdominal cavity and surgical anastomosis ; . Abdominal wall fat, epiploic fat, and colonic wall tissue samples were collected simultaneously. Antibiotic concentrations were determined by high-performance liquid chromatography. Increasing the dose of clavulanic acid to 400 mg resulted in significantly higher peak and trough levels in serum P 0.03 ; . Following the injection of 400 mg, mean concentrations of clavulanic acid in the fatty tissues were significantly increased at the time of opening P 0.02 ; . The concentrations of clavulanic acid and amoxicillin in fatty tissues were 17 to 52% and 12 to 23% of the levels in sera, respectively. In the colonic wall, the concentrations of clavulanic acid and amoxicillin were 52 to 63% and 49 and 27% of the levels in sera, respectively. In sera, clavulanic acid given at a dose of 200 or 400 mg reached or exceeded the concentrations found to be effective in vitro to reduce the MICs of amoxicillin from the resistant to the susceptible category for 90% of the potential pathogens. In most of the tissues investigated, increasing the dose of clavulanic acid to 400 mg resulted in a significantly higher number of samples with concentrations found to be effective in vitro 72 versus 11%; P 0.05 ; . In conclusion, increasing the dose of clavulanic acid to 400 mg resulted in higher levels in sera and improved penetration into the abdominal tissues in patients undergoing colorectal surgery. Colorectal surgery is a ``contaminated-aseptic surgery, '' and prophylactic antibiotics are widely used prior to and during surgery, and the importance of the prophylactic antibiotics in reducing postoperative infections and mortality has been demonstrated 2, 3, 13, ; . Antibiotics are used to prevent both wound infections and peritonitis which may be caused by intraoperative contamination. Antibiotics are selected on the basis of the ability to eradicate the bacteria most likely to contaminate a surgical wound: Escherichia coli and various members of the family Enterobacteriaceae, Enterococcus faecalis, Staphylococcus aureus, Bacteroides fragilis, and other anaerobic bacteria 2, 3, 13, ; . The basic concept underlying the optimal use of antibiotic prophylaxis is that an adequate amount of an appropriate antibiotic should be present in the blood and tissues before a bacterial challenge. It seems clear that during a surgical procedure, adequate antibiotic concentrations should be achieved at all sites of potential infection. Also, antibiotic activity should be maintained throughout the procedure, from incision to closure 4, 6, 8, ; . Amoxicillin-clavulanic acid has been widely used as a prophylactic antibiotic in abdominal and gynecological surgery 11, 24 ; . It is effective in the prevention of wound infections in. This decision can be contrasted with Lek Pharmaceutical and Chemical Company DD v Smithkline Beecham plc10 and Shino Kaneko v Nemoto &Co Ltd11 discussed below. Lek Pharmaceutical and Chemical Company DD v Smithkline Beecham plc concerned a patent application by Smithkline Beecham claiming the use of a combination of amoxycillin and clavulanic acid in set ratios to reduce the gastric irritancy in the treatment of bacterial infections in paediatric patients. The Patent Office found that although comparable ratios were disclosed in prior art, the prior art did not reveal that varying the ratios reduced irritancy. Lek opposed the patent on the grounds of lack of novelty and inventive step, together with other grounds. The hearing officer found that these arguments failed because Lek did not lead evidence to counter the unexpected result of Smithkline Beecham's new acid ratio. The hearing officer also said that Lek's analysis seemed to have been prepared with the benefit of hindsight. In Shino Kaneko v Nemoto &Co Ltd, a patent application claimed a ratio of phosphorescent phosphor that provided afterglow characteristics superior to previous models. The Patent Office held the application was novel because it disclosed a ratio substantially dissimilar to that in the parent application. Further, the application was inventive because the new ratio had superior stability, lifespan, and afterglow than previous models. Importantly, the prior art failed to provide a teaching that would directly lead the skilled addressee, as a matter of course, to the invention as stated in the parent patent. The issue of varying combinations, changing formulas, and improving characteristics of known products will remain litigious. Several best selling drugs come off patent in a few years, 12 and originators will look at re-working combinations of known products to extend patent life, with generic manufacturers likely to challenge such practices.
Respectively. The same is true for other deficiencies, like acetylation, sulfoxidation, glucagon synthetase and so on. Another very interesting question is the fact that HLA haplotypes thus the genetic characteristics of the host can influence some drug-induced hepatotoxicity, and I will show you a nice exemple of that with the case of clavulanic acid. I will not talk about the problem of direct toxicity related to reactive metabolites since the subject will be covered by Dr. Dart. I will now consider the problem of the postulated mechanism involved in indirect type B hepatotoxicity. The hypothesis to explain this kind of phenomenon is the following: an alkylated protein is released by a dying hepatocyte. This small complex is taken by the Kupffer's cell and transformed in an alkylated peptide which will be presented at the surface of the Kupffer's cell by the HLA complex. This complex is then recognized by a CD4 cell which will help various immunological mechanisms such as CD8 cytotoxic T cells, B cells and plasmocytes giving rise to cytotoxicity and antibody production. You will probably ask me how those adducts can be expressed on the cell surface. Following Robin's hypothesis from Paris this may be due to the trafficking of a vesicular form of cytochrome P450 in which both cytochrome P450 and the protein adduct are transported to the hepatocyte membrane where they act as target for the immunological reaction. And there is, also, a hypothesis explaining the fact that in some of those immune toxicities you can observe antibodies directed against the metabolite cytochrome P450 adduct but also, to the P450 itself.That is a well-known phenomenon in tienilic acid toxicity where you can find in the blood anti-LKM2 antibody or in halothane hepatitis in which you can find in the blood antiCyp2E1 antibodies. Clavulanic acid gives rise to a very peculiar and interesting type of hepatotoxicity which for the clinician, is generally preceded by a slight episode of hepatitis followed by prolong cholestasis which can last for months and even in very rare instances, induce bile duct lesions closed to the vanishing bile duct syndrome which consists into the disappearance of the small interlobular bile ducts. This is an example of this bile duct lesion induced by clavulanic acid. You see that this small bile duct, what we call the interlobular bile duct contained in the portal tract has been somewhat destroyed with inflamThe Toxicology Forum-European Meeting 2001.